The current lack of diversity in genomic research data is hindering what we can learn about health and potential treatments in our global population. By enhancing the diversity of people participating in genomic research, we can advance our knowledge and discovery of human genetics for all populations. To that end, The Charles Bronfman Institute for Personalized Medicine is spearheading the effort to carry out the genetic sequencing of one million Mount Sinai patients within the next five years. This initiative, one of the largest such sequencing projects of its kind, will integrate health and research data at Mount Sinai to promote discoveries that will directly benefit our patient population. Learn more about Mount Sinai Million.  

The research interests of the Translational Initiatives for Pharmacogenomics (TIP) program are two-fold. Primarily, we seek to develop and successfully implement best practices for the clinical adoption of pharmacogenomics and personalized medicine. In addition, we are actively engaged in multiple research activities that seek to enhance the evidence base needed for clinical translation of certain significant drug-gene interactions. We are also trying to bridge the knowledge gap that exists between researchers and clinical providers. Learn more about TIP

BioMe provides essential research infrastructure and genotype-phenotype datasets for multi-disciplinary, programmatic research grants. Our faculty lead active federal grants – all funded by the National Institutes of Health (NIH). Learn more about our NIH funded programs

We are leading the radical movement toward diagnoses and classification of disease according to a patient’s molecular profile, accommodating differences at all possible levels of exposure (genome plus environment plus lifestyle) and at all stages of the process, from prevention to post-treatment follow-up. This type of personalized medicine drives our Institute's research. Learn more about our program